CD47 and hepatocellular carcinoma: Importantly, binding of Pal/NRF-1 to the CD47 promoter was also previously reported in human neuroblastoma and hepatoma cell lines (37), as well as, during arising resistance to the oncogenic B-RAF molecular inhibitors (38).